UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 186

Sortiert nach

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma

Blood, 2016-09, Vol.128 (13), p.1735-1744

2016

Volltextzugriff (PDF)

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

Haematologica (Roma), 2012-11, Vol.97 (11), p.1761-1767

2012

Volltextzugriff (PDF)

Mechanism of action of lenalidomide in hematological malignancies

Journal of hematology and oncology, 2009-08, Vol.2 (1), p.36-36, Article 36

2009

Volltextzugriff (PDF)

Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma

PloS one, 2013-09, Vol.8 (9), p.e74191-e74191

2013

Volltextzugriff (PDF)

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

Blood, 2011-09, Vol.118 (13), p.3512-3524

2011

Volltextzugriff (PDF)

Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease

Blood, 2014-04, Vol.123 (16), p.2504-2512

2014

Volltextzugriff (PDF)

Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis

The Journal of immunology (1950), 2013-03, Vol.190 (6), p.2966-2975

2013

Volltextzugriff (PDF)

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma

Clinical cancer research, 2016-12, Vol.22 (23), p.5783-5794

2016

Volltextzugriff (PDF)

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance

Blood, 2012-08, Vol.120 (8), p.1597-1600

2012

Volltextzugriff (PDF)

Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results

Journal of cancer research and clinical oncology, 2021-02, Vol.147 (2), p.619-631

2021

Volltextzugriff (PDF)

Multi-Subgroup Gene Screening Using Semi-Parametric Hierarchical Mixture Models and the Optimal Discovery Procedure: Application to a Randomized Clinical Trial in Multiple Myeloma

Biometrics, 2018-03, Vol.74 (1), p.313-320

2018

Volltextzugriff (PDF)

Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma

Blood, 2015-06, Vol.125 (24), p.3756-3759

2015

Volltextzugriff (PDF)

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)

Haematologica (Roma), 2015-09, Vol.100 (9), p.1214

2015

Volltextzugriff (PDF)

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

Blood cancer journal (New York), 2024-02, Vol.14 (1), p.24-24, Article 24

2024

Volltextzugriff (PDF)

Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis

BMC bioinformatics, 2014-10, Vol.15 Suppl 11 (Suppl 11), p.S9-S9, Article S9

2014

Volltextzugriff (PDF)

In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes

Genes chromosomes & cancer, 2014-07, Vol.53 (7), p.549-557

2014

Volltextzugriff (PDF)

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

Annals of hematology, 2021-04, Vol.100 (4), p.1065-1077

2021

Volltextzugriff (PDF)

Leveraging the new with the old: providing a framework for the integration of historic microarray studies with next generation sequencing

BMC bioinformatics, 2014-10, Vol.15 Suppl 11 (Suppl 11), p.S3-S3, Article S3

2014

Volltextzugriff (PDF)

Towards the integration, annotation and association of historical microarray experiments with RNA-seq

BMC bioinformatics, 2013-10, Vol.14 Suppl 14 (S14), p.S4-S4, Article S4

2013

Volltextzugriff (PDF)

Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2014-06, Vol.14 (3), p.211-214

2014

Volltextzugriff (PDF)

Reply to "Metronomic chemotherapy beyond misconceptions"--Haematologica 2013;98(11):e145

Haematologica (Roma), 2013-11, Vol.98 (11), p.e149-e150

2013

Volltextzugriff (PDF)

1 – 25 von 186

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(169)
Mit Volltextzugriff
(168)

Publikationsform

Sprache

Englisch
(185)
Japanisch
(16)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(92)
Methods In Molecular Biology
(13)
Multiple Myeloma
(13)
Clinical Lymphoma, Myeloma And Leukemia
(7)
Journal Of Clinical Oncology
(7)
Haematologica
(5)
Urology
(5)
Bmc Bioinformatics
(4)
Clinical Cancer Research
(4)
Hemasphere
(4)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Mechanism of action of lenalidomide in hematological malignancies

Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance

Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results

Multi-Subgroup Gene Screening Using Semi-Parametric Hierarchical Mixture Models and the Optimal Discovery Procedure: Application to a Randomized Clinical Trial in Multiple Myeloma

Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis

In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

Leveraging the new with the old: providing a framework for the integration of historic microarray studies with next generation sequencing

Towards the integration, annotation and association of historical microarray experiments with RNA-seq

Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma

Reply to "Metronomic chemotherapy beyond misconceptions"--Haematologica 2013;98(11):e145

Suchergebnisse filtern